Extended-release of Octreotide (LF-PB) for the Treatment of Seroma

Inclusion Criteria: * Signed informed consent form; * Undergoing breast cancer surgery with axillary lymph node dissection during the current clinical trial; * Negative serum pregnancy test for women of childbearing potential; * Aspartate aminotransferase and alanine aminotransferase \< 2 x the upper limit of normal; * ECOG PS ≤ 1. Exclusion Criteria: * Previous axillary surgery on the same armpit (sentinel lymph node surgery is not exclusionary); * Previous radiotherapy within five years from study drug administration on the same armpit undergoing surgery in this study; * Concomitant participation to other clinical trial; * Uncontrolled diabetes; * Cholelithiasis; * Human immunodeficiency virus or hepatitis B or C by screening serology; * Uncontrolled hypothyroidism: if patient is being administered Eutirox/ Levothyroxine (or analogues) and levels of T3, T4 and TSH are confirmed to be within the normal ranges at screening, the patient can be enrolled in this study; * Pregnant or lactating; * Ascertained or presumptive hypersensitivity to the active principle and/or the ingredients of the study drug formulation; * Corrected QT (using the Bazett formula, QTc) interval at screening or baseline \> 450 msec (as the mean of 3 consecutive readings 5 minutes apart); * Presence of any disease or use of concomitant medication known to increase the QT interval; * Clinically significant or relevant abnormal medical history, vital sign, physical examination or laboratory evaluation finding; * Corticosteroid treatment on a long-term basis (i.e. treatment for more than 3 consecutive days); * Current or recurrent disease that could affect the results of the clinical or laboratory assessment required for the study.